235 related articles for article (PubMed ID: 29727211)
21. Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer.
Boudrias-Dalle E; Cloutier M; Harvey M; Leblanc G; Besner-Morin O; Adam JP
J Oncol Pharm Pract; 2019 Jan; 25(1):239-243. PubMed ID: 28950807
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations.
Geisler AN; Noor SJ
J Drugs Dermatol; 2020 Sep; 19(9):894-896. PubMed ID: 33026750
[TBL] [Abstract][Full Text] [Related]
23. Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.
Ketzer S; Schimmel K; Koopman M; Guchelaar HJ
Clin Pharmacokinet; 2018 Apr; 57(4):455-473. PubMed ID: 28853050
[TBL] [Abstract][Full Text] [Related]
24. Dermatologic Toxicities: A Chart Review of Clinical Management Among Patients With Metastatic Colorectal Cancer Treated With Panitumumab.
Lowe KA; Sangaré L; Roehl KA; Jung S; Kafatos G; Garwin T
Clin J Oncol Nurs; 2019 Apr; 23(2):157-164. PubMed ID: 30880806
[TBL] [Abstract][Full Text] [Related]
25. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review.
Fornasier G; Francescon S; Baldo P
Adv Ther; 2018 Oct; 35(10):1497-1509. PubMed ID: 30218345
[TBL] [Abstract][Full Text] [Related]
26. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
[TBL] [Abstract][Full Text] [Related]
27. Panitumumab-induced pulmonary toxicity.
Arora R; Kisiel M; MacColl C
Curr Oncol; 2019 Oct; 26(5):e700-e702. PubMed ID: 31708664
[TBL] [Abstract][Full Text] [Related]
28. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
Wen F; Li Q
World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported symptoms and stepwise symptom management in patients on epidermal growth factor inhibitors: A retrospective, descriptive cohort study.
Koldenhof JJ; Langenberg MHG; Witteveen PO; Teunissen SCCM
Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12800. PubMed ID: 29314360
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
31. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
[TBL] [Abstract][Full Text] [Related]
32. [Epidermal growth factor receptor inhibitors side effects].
Guhl G; González-de Arriba A; Daudén E
Actas Dermosifiliogr; 2006 Jun; 97(5):296-310. PubMed ID: 16956561
[TBL] [Abstract][Full Text] [Related]
33. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
34. Reversible cicatricial ectropion associated with EGFR inhibitors.
Scofield-Kaplan S; Todaro J; Winn BJ
Orbit; 2018 Oct; 37(5):364-367. PubMed ID: 29336655
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
36. Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study on the Efficacy and Safety of Vitamin K1 Ointment for Cetuximab or Panitumumab-Induced Acneiform Eruptions-VIKTORIA Study.
Hashimoto H; Iwasa S; Yanai-Takahashi T; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamazaki N; Kato Y
Gan To Kagaku Ryoho; 2020 Jun; 47(6):933-939. PubMed ID: 32541171
[TBL] [Abstract][Full Text] [Related]
37. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
38. Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
Ke YT; Kuo CC
Adv Skin Wound Care; 2017 Jan; 30(1):27-34. PubMed ID: 27984271
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma.
Chen J; Wang J; Ni T; He H; Zheng Q
Medicine (Baltimore); 2020 Jun; 99(25):e19908. PubMed ID: 32569154
[TBL] [Abstract][Full Text] [Related]
40. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
